Trimethylamine-containing compounds for diagnosis and prediction of disease
AssigneeThe Cleveland Clinic Foundation
InventorsStanley L. Hazen, Zeneng Wang, Bruce S. Levison
Life of this patent
Estimating the term…
Abstract
The present invention provides markers and methods for determining whether a subject, particularly a human subject, has or is at risk of developing, a disease such as cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD (Nonalcoholic Fatty Liver Disease) or NASH (Nonalcoholic Steatohepatitis) (e.g., within the ensuing year, two years, and/or three years). The present application also relates to the use of such markers and methods for monitoring the status of such diseases in a subject or the effects of therapeutic agents on subjects with such diseases.
Claims19
A method of identifying a subject having or at risk of cardiovascular disease or at risk of a complication of cardiovascular disease, comprising:
- a) determining levels of a trimethylamine (TMA)-containing compound in a biological sample obtained from the subject, wherein the TMA-containing compound is selected from crotonobetaine, gamma-butyrobetaine, or carnitine;
- and
- b) comparing levels of said TMA-containing compound in said biological sample to a control value;
- wherein a subject whose levels of said TMA-containing compound in said biological sample are elevated as compared to said control value has or is at risk for developing cardiovascular disease or a complication of cardiovascular disease.
A method of identifying a subject as having or at risk of developing:
- diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD, or NASH, comprising:
- a) determining levels of trimethylamine (TMA)-containing compound in a biological sample obtained from the subject;
- and
- b) comparing levels of said TMA-containing compound in said biological sample to a control value;
- wherein a subject whose levels of said TMA-containing compound in said biological sample are elevated as compared to said control value is at risk of developing, or has:
- diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD, or NASH.
A method of treating, or preventing the development of, a condition comprising;
- administering antibiotics to a subject such that the formation of trimethylamine, TMANO, crotonobetaine, and/or gamma-butyrotetaine from carnitine in said subject is reduced thereby at least partially treating, or preventing the development of, a condition selected from the group consisting of:
- cardiovascular disease, diabetes mellitus, insulin resistance, metabolic syndrome, NAFLD, or NASH.
Dependencies are inferred from the claim text.